Gamma radiation exposure of accompanying persons due to Lu-177 patients

Neuroendocrine tumours (NET) are cancers usually observed and arisen in the stomach, intestine, pancreas and breathing system. Recently, radionuclide therapy applications with Lu-177 peptide compound are rapidly growing; especially effective clinical results are obtained in the treatment of well-dif...

Full description

Saved in:
Bibliographic Details
Published inEPJ Web of Conferences Vol. 100; pp. 3002 - 1-03002-2
Main Authors Kovan, Bilal, Demir, Bayram, Tuncman, Duygu, Capali, Veli, Turkmen, Cuneyt
Format Journal Article Conference Proceeding
LanguageEnglish
Published Les Ulis EDP Sciences 01.01.2015
Subjects
Beta rays
Breathing
Emittance
Emitters
Exposure
Gamma rays
Intestines
Medical services
Pancreas
Patients
Radiation effects
Radiation protection
Radiation therapy
Radiochemistry
Radioisotopes
Stomach
Online AccessGet full text

Cover

More Information
Summary:Neuroendocrine tumours (NET) are cancers usually observed and arisen in the stomach, intestine, pancreas and breathing system. Recently, radionuclide therapy applications with Lu-177 peptide compound are rapidly growing; especially effective clinical results are obtained in the treatment of well-differentiated and metastatic NET. In this treatment, Lu-177-DOTA, a beta emitter radioisotope in the radiopharmaceutical form, is given to the patient by intravenous way. Lu-177 has also gamma rays apart from beta rays. Gamma rays have 175 keV average energy and these gamma rays should be under the control in terms of radiation protection. In this study, we measured the exposure dose from the Lu-177 patient.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2100-014X
2101-6275
2100-014X
DOI:10.1051/epjconf/201510003002